Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents

Gastroenterología y hepatología
Yago González-LamaLluís Abreu

Abstract

Immunosuppressive or biological treatment in patients with inflammatory bowel disease can modify the natural history of their disease, although these treatments are not universally effective and can have severe adverse effects. Attempts have been made to identify predictive factors of response to the various therapeutic options in order to aid the choice of the most appropriate therapeutic alternative in each patient. The possibility of modifying any one of these predictive factors would be of great interest since it would provide the opportunity to alter the course of the disease. Epidemiological, biological, clinical, endoscopic, radiological, genetic and even proteomic markers have been studied, in addition to others related to the disease itself or to specific treatments. The present article briefly discusses the real use of each of these markers and the evidence supporting their utility.

References

Oct 1, 1990·Gastroenterology·P RutgeertsM Hiele
Jul 1, 1994·Diseases of the Colon and Rectum·P J LunnissR K Phillips
Jun 1, 1996·Gut·S P TravisD P Jewell
Oct 28, 1999·Gastrointestinal Endoscopy·G D'HaensP Rutgeerts
May 2, 2000·Diseases of the Colon and Rectum·K S ChappleN S Ambrose
Jan 11, 2001·The American Journal of Gastroenterology·R D CohenS B Hanauer
Nov 1, 2001·Journal of Pediatric Gastroenterology and Nutrition·S Kugathasan
Feb 13, 2002·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·B SiciliaF Gomollón
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Jul 10, 2002·Gastroenterology·Severine VermeireUNKNOWN Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France
Aug 29, 2002·Gastroenterology·Mansour A ParsiAaron Brzezinski
Sep 25, 2002·Alimentary Pharmacology & Therapeutics·A AnsariJ Sanderson
Oct 3, 2002·The American Journal of Gastroenterology·Severine VermeireUNKNOWN Belgian Group of Infliximab Expanded Access Program in Crohn's Disease
Feb 4, 2003·Alimentary Pharmacology & Therapeutics·S J BellM A Kamm
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Mar 28, 2003·Radiologic Clinics of North America·Clive Bartram, Gordon Buchanan
Jun 5, 2003·Drugs of Today·J. A. Tibble, I. Bjarnason
Jun 26, 2003·Alimentary Pharmacology & Therapeutics·I D R ArnottJ Satsangi
Jul 19, 2003·Alimentary Pharmacology & Therapeutics·J-M GornetM Lemann
Nov 7, 2003·Current Gastroenterology Reports·Eric Vasiliauskas
Nov 7, 2003·Current Gastroenterology Reports·William J Sandborn
Feb 6, 2004·Gastroenterology·Paul RutgeertsStephen B Hanauer
Feb 6, 2004·Gastroenterology·Matthew RutterAlastair Forbes
May 1, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Carmen CuffariTheodore M Bayless
May 29, 2004·Gastroenterology·Paul RutgeertsSéverine Vermeire
Jun 15, 2004·American Journal of Physiology. Gastrointestinal and Liver Physiology·Steven H Itzkowitz, Xianyang Yio
Jun 30, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Stephen B HanauerPaul Rutgeerts
Jul 3, 2004·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·M Luna-ChadidJ Maté Jiménez
Jul 23, 2004·Journal of Pediatric Gastroenterology and Nutrition·George H Russell, Aubrey J Katz
Aug 18, 2004·Digestive Diseases and Sciences·Stephan BuderusMichael J Lentze
Oct 12, 2004·Inflammatory Bowel Diseases·David S FeffermanRichard J Farrell
Oct 12, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Bruce E SandsUNKNOWN ACCENT II Study
Nov 24, 2004·Advanced Drug Delivery Reviews·Chinyu Su, Gary R Lichtenstein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.